How Ph.D. was paid
$3.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Michael S. Exton, Ph.D.Chief Executive Officer and Director | $650,576 | $483,822 | $1,049,304 | $1,355,231 | $15,020 | $3,553,953 |
| Scott M. CoianteSenior Vice President and Chief Financial Officer | $444,172 | $187,200 | $334,093 | $577,866 | $14,915 | $1,558,246 |
| Brian T. CrumSenior Vice President and General Counsel | $489,926 | $180,035 | $354,791 | $458,227 | $17,405 | $1,500,384 |
| Craig B. Granowitz, M.D., Ph.D.Senior Vice President and Chief Medical Officer | $519,344 | $253,971 | $421,712 | $544,662 | $16,220 | $1,755,909 |
| Wendy E. McDermottSenior Vice President, Human Resources | $415,758 | $149,835 | $301,060 | $388,840 | $14,853 | $1,270,346 |
What changed and why
- $3.6MMichael S. Exton received total compensation of $3,553,953 as chief executive officer in 2025.
- Stock and option awards represented a significant portion of executive compensation aligned with long-term stockholder value.
- 96%Over 96% of the votes cast at the 2025 annual meeting approved the named executive officer compensation.
- Pearl Meyer served as the independent compensation consultant to assess executive and director compensation competitiveness.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.